Ocata Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

OCAT 8.46 -0.01 (-0.12%)
price chart
Ocata Therapeutics Inc.
Ocata Therapeutics Inc. NASDAQ: OCAT. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
Astellas to Acquire Ocata Therapeutics
9, 2015 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata"), a biotechnology company focused on the research and ...
Ocata Therapeutics (OCAT) to be Acquired by Astellas in $379M Deal  StreetInsider.com
Astellas Pharma To Acquire Ocata Therapeutics For US$8.50/shr In Cash  Nasdaq
Ocata Therapeutics Inc (OCAT) Cut to "Hold" at Zacks Investment Research
According to Zacks, “Ocata Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on the development and commercialization of regenerative ophthalmology therapeutics.
Zacks Investment Research Lowers Ocata Therapeutics Inc (OCAT) to Hold  IRA Market Report
Ocata Therapeutics Inc (OCAT) Stock Rating Lowered by Zacks Investment Research  Corvus Business Newswire
Ocata Therapeutics, Inc. (OCAT) Recent Analyst Updates
A number of investment brokers have recently updated their price targets on shares of Ocata Therapeutics, Inc. (OCAT).
Sorting Out Ocata Management's Words And Deeds
What has bothered me about the recent lowball tender offer by Astellas Pharma, Inc. on November 9, 2015, are the apparent statements by the executives of Advanced Cell Technology/Ocata Therapeutics, both past and present, compared with their actions.
Ocata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate
Ocata Therapeutics majority shareholders (NASDAQ: OCAT) have again, after this third offer, indicated that its Board of Directors has erred in its unanimous recommendation for the solicited tender offer by Astellas to acquire all of the outstanding ...
Hot Biotech Stocks To Watch Right Now: Sarepta Therapeutics, Inc. (SRPT ...  iStreetWire
Angry investors say Ocata Therapeutics undervalued in sale
Executives struck a triumphant tone last month when Ocata Therapeutics Inc., of Marlborough, said it had agreed to be sold to the Japanese drug maker Astellas Pharma Inc., in a $379 million deal that promised a nearly 80 percent premium over Ocata's ...
Short Interest in Ocata Therapeutics Inc (OCAT) Declines By 45.6%  Intercooler
Ocata Therapeutics: Are You Watching A Bluebird Go By?
Ocata Therapeutics has, at last, executed an up-list to the Nasdaq and funded its operations through periods of new clinical and business development.
Ocata Therapeutics Science For The Lay Person
To understand the value of Ocata Therapeutics (NASDAQ:OCAT), it is important to hear, and read, what its Chief Scientific Officer has to say about his research, as well as some of their clinical trial investigators.
Astellas extends Ocata Therapeutics tender offer until February 9
In order to give Ocata Therapeutics (OCAT +1.6%) shareholders more time to tender their shares, Astellas Pharma (OTCPK:ALPMF)(OTCPK:ALPMY) extends its offering period to 5:00 pm ET February 9. The most recent period expired yesterday at 5:00 pm ...
Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata ...  FierceBiotech
Ocata Therapeutics Reports Tender Offer Extension by Astellas Until Feb. 9 ...  WallStreet.org